WPG Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

WPG Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$446	Hold	18	–	–	﹤0.01%	1373
2025 Q4	$420	Hold	18	–	–	﹤0.01%	1402
2025 Q3	$355	Hold	18	–	–	﹤0.01%	1397
2025 Q2	$391	Hold	18	–	–	﹤0.01%	1371
2025 Q1	$437	Hold	18	–	–	﹤0.01%	1362
2024 Q4	$376	Buy	+18	New	+$387	﹤0.01%	1385

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

WPG Advisers's CPRX Position: Q1 2026 in Review

WPG Advisers held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 18 shares worth $446. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

WPG Advisers first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

WPG Advisers held 18 shares of Catalyst Pharmaceutical worth $446 as of Q1 2026.
WPG Advisers left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of WPG Advisers's portfolio in Q1 2026, its #1373 holding.
WPG Advisers first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on WPG Advisers's 13F filing for Q1 2026, filed 30 Apr 2026.